Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

ClinicalTrials.gov ID: NCT07067463

Public ClinicalTrials.gov record NCT07067463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 3:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.

Study identification

NCT ID
NCT07067463
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Enrollment
705 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 22, 2026
Primary completion
May 31, 2030
Completion
Jun 30, 2030
Last update posted
Sep 9, 2026

2026 – 2030

United States locations

U.S. sites
16
U.S. states
12
U.S. cities
15
Facility City State ZIP Site status
Arizona Neuroscience Research, LLC Pheonix Arizona 85032 Recruiting
Perseverance Research Center Scottsdale Arizona 85253 Recruiting
Regina Berkovich MD, PhD Inc. West Hollywood California 90048 Recruiting
Nova Clinical Research, LLC Bradenton Florida 34209 Recruiting
Neurology Associates, PA Maitland Florida 32751 Recruiting
KC Research Center, PA Neurology Research Department Roeland Park Kansas 66205 Recruiting
Washington University School of Medicine St Louis Missouri 63110 Recruiting
Cooperman Barnabas Medical Center Livingston New Jersey 07039 Recruiting
Velocity Clinical Research, Raleigh Neurology Raleigh North Carolina 27607 Recruiting
The Ohio State University Wexner Medical Center (OSUWMC) L3-100 Columbus Ohio 43221 Recruiting
The Boster Center for Multiple Sclerosis Columbus Ohio 43235 Recruiting
Premier Neurology Greenville South Carolina 29605 Recruiting
Neurology Clinic, P.C. Cordova Tennessee 38018 Recruiting
Lone Star Neurology San Antonio Texas 78258 Recruiting
Texas Institute for Neurological Disorders Sherman Texas 75092 Recruiting
Medical College of Wisconsin Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07067463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2026 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07067463 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →